查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1873986

抗病毒藥物抗藥性市場

Antiviral Drug Resistance Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

預計抗病毒藥物抗藥性市場將從 2024 年的 37.1 億美元成長到 2031 年的 63.5 億美元，2031 年至 2031 年的年複合成長率(CAGR) 為 7.9%。推動該市場成長的主要趨勢包括肝病發病率上升、愛滋病毒和愛滋病的持續流行以及發展中國家對高品質產品的需求不斷成長。

抗病毒藥物抗藥性市場分析

近年來，全球愛滋病毒/愛滋病的感染率顯著上升。後天免疫缺乏症候群（愛滋病）是一種慢性且可能致命的疾病，由人類免疫缺乏病毒（HIV）引起，該病毒會嚴重損害免疫系統，削弱人體抵抗感染的能力。 HIV進入人體後，患者可能在一個月內出現類似流感的症狀，這被稱為原發性或急性HIV感染，永續數週。根據美國衛生與公共服務部和部長少數族裔愛滋病計劃基金（SMAIF）的數據，2022年全球約有3,900萬人感染HIV/愛滋病，其中有相當一部分居住在中低收入國家。例如，印度國家資訊中心發布的《2017年印度愛滋病毒感染率估計報告》估計，印度的HIV感染率為0.22%（範圍在0.16%至0.30%之間）。此外，據估計，印度男性成人HIV感染率為0.25%（0.18%-0.34%），女性為0.19%（0.14%-0.25%）。因此，預計在預測期內，印度病毒感染病例的增加將推動對抗病毒藥物抗藥性解決方案的需求成長。

抗病毒藥物抗藥性市場概覽

肝炎發病率的上升和愛滋病毒/愛滋病感染率的不斷攀升正在推動市場成長。此外，新興市場的擴張也可能在預測期內對需求產生正面影響。然而，替代療法的出現可能會阻礙市場成長。近年來，美國的愛滋病毒感染率上升。美國衛生與公眾服務部及美國愛滋病資訊基金會（SMAIF）的數據顯示，2021年美國新增愛滋病毒感染者近3,2100人。預計這些因素將在整個預測期內推動北美抗病毒藥物抗藥性市場的成長。

戰略洞察

抗病毒藥物抗藥性市場的促進因素和機會

肝病發病率上升將有利於市場

病毒是微小的病原體，可導致多種傳染病，包括流感、普通感冒和疣，以及天花、愛滋病和伊波拉等嚴重疾病。它們在宿主細胞內複製，並能侵入任何健康的活細胞，不斷增殖產生更多病毒。不同的病毒會攻擊體內特定的細胞，例如肝臟、大腦、皮膚、血液以及生殖系統、呼吸系統和消化系統等各個系統中的細胞。近年來，病毒感染，尤其是肝炎的發生率在全球範圍內上升。肝炎可導致肝臟損傷和炎症，構成重大的全球健康挑戰，並可能導致慢性感染，增加肝硬化和肝癌的死亡風險。肝炎分為甲型、乙型、丙型、丁型和戊型，每種類型的傳播途徑都不同。根據世界衛生組織（世衛組織）統計，B型肝炎的盛行率最高的地區是非洲和西太平洋地區，成人感染率分別為6.1%和6.2%。

新興市場醫療保健投資不斷成長

新興市場，特別是亞太地區以及中南美洲，醫療保健支出不斷成長，推動了聚合酶鍊式反應（PCR）和新一代定序等先進技術在多種病毒性疾病治療方案開發中的應用。美國國家癌症研究所（NCI）等機構正在資助愛滋病毒和愛滋病相關惡性腫瘤的研究，以了解慢性愛滋病毒感染者老化如何影響癌症風險、類型和生物學特徵。中國、日本和巴西等國正大力投資醫療保健，以增強其市場佔有率，並確保醫院、研究機構和診斷實驗室能夠有效利用醫療器材和試劑。

抗病毒藥物抗藥性市場細分分析

抗病毒藥物抗藥性市場分析按類型、疾病適應症、技術和最終用戶進行細分。

  • 按類型分類，市場分為試劑盒和試劑、儀器，其中試劑盒和試劑在 2023 年佔據最大的市場佔有率。
  • 按疾病適應症分類，市場分為 HIV、肝炎和鉅細胞病毒 (CMV)，其中 HIV 部分在 2023 年佔據最大佔有率。
  • 從技術角度來看，市場包括免疫診斷、聚合酶鍊式反應 (PCR)、次世代定序 (NGS) 等，其中免疫診斷在 2023 年將佔據相當大的市場佔有率。
  • 按最終用戶分類，市場分為醫院和診所、病理或診斷實驗室以及研究機構，其中醫院和診所在 2023 年佔據最大佔有率。

抗病毒藥物抗藥性市場的地理分析

抗病毒藥物抗藥性市場報告的地理範圍分為五個區域：北美、亞太、歐洲、中東和非洲以及南美和中美洲。北美在抗病毒藥物抗藥性市場中佔據最大佔有率，這主要受多種因素驅動，例如愛滋病毒和肝炎等病毒感染的流行以及政府資助的國家計畫。近年來，美國的愛滋病毒感染率上升，2021年報告的新增感染病例約為32,100例。預計亞太地區在未來幾年將實現最高的複合年成長率。

抗病毒藥物抗藥性市場報告範圍

抗病毒藥物抗藥性市場的最新發展

抗病毒藥物抗藥性市場評估是基於從一手和二手研究中收集的定性和定量資料，包括重要的企業出版物、協會資料和資料庫。抗病毒藥物抗藥性市場的主要發展包括：

  • 強生旗下楊森製藥宣布，其早期臨床候選藥物（JNJ-1802）在《自然》雜誌上發表了最新資料，顯示該藥物對非人靈長類動物和小鼠具有強效的登革熱防護作用。這款首創的抗病毒藥物在I期臨床試驗中證實安全且耐受性良好，目前正推進至II期臨床試驗，用於登革熱的預防和治療。 （圖片來源：強生公司，新聞稿，2023年3月）
  • 印度藥品管理總局 (DCGI) 已授予印度西普拉有限公司 (Cipla Limited) 緊急使用授權 (EUA)，允許其在印度推出莫努匹拉韋 (Molnupiravir)，該藥物將以 Cipmolnu® 為品牌名進行銷售。莫努匹拉韋是第一個獲得英國藥品和保健產品監管局 (MHRA) 批准的口服抗病毒藥物，用於治療輕度至中度 COVID-19 患者，尤其適用於有重症風險的患者。 （圖片來源：西普拉，新聞稿，2021 年 5 月）

抗病毒藥物抗藥性市場報告的覆蓋範圍和交付成果

這份題為《抗病毒藥物抗藥性市場規模及預測（2021-2031）》的報告對市場進行了全面分析，涵蓋以下領域：

  • 全球、區域和國家層級所有關鍵細分市場的抗病毒藥物抗藥性市場規模和預測。
  • 市場趨勢和動態，包括促進因素、限制因素和主要機會。
  • 詳細的PEST/波特五力模型和SWOT分析。
  • 市場分析涵蓋關鍵趨勢、全球和區域框架、主要參與者、法規和最新發展。
  • 產業格局和競爭分析，包括市場集中度、熱力圖分析、主要參與者以及抗病毒藥物抗藥性市場的最新發展。
  • 深入的公司概況。

目錄

第1章：引言

第2章：全球抗病毒藥物抗藥性市場及主要結論

第3章：研究方法

  • 覆蓋範圍
  • 二手研究
  • 初步研究

第4章：全球抗病毒藥物抗藥性市場概況

  • 概述
  • PEST分析
    • 北美PEST分析
    • 歐洲 PEST 分析
    • 亞太地區PEST分析
    • 中東和非洲 PEST 分析
    • 南美洲和中美洲 PEST 分析
  • 專家意見
  • 按測試類型分類的測試成本
  • 按地區分類的測試量

第5章：全球抗病毒藥物抗藥性市場及關鍵產業動態

  • 主要市場促進因素
    • 肝炎疾病發生率上升
    • 愛滋病毒/愛滋病感染率不斷上升
  • 主要市場限制因素
    • 替代方案
  • 主要市場機遇
    • 新興市場醫療保健支出不斷成長
  • 未來趨勢
    • 對更高品質產品的需求
  • 影響分析

第6章：抗病毒藥物抗藥性市場及全球分析

  • 全球抗病毒藥物抗藥性市場收入預測與分析
  • 全球抗病毒藥物抗藥性市場（依地理分類）－預測與分析
  • 關鍵參與者的定位

第7章：全球抗病毒藥物抗藥性市場分析及產品細分

  • 概述
  • 2018 年及 2031 年全球抗病毒藥物抗藥性市場佔有率（按產品分類）
  • 試劑盒和試劑
  • 儀器

第8章：全球抗病毒藥物抗藥性市場分析及依疾病指徵分類

  • 概述
  • 2018 年及 2031 年全球抗病毒藥物抗藥性市場佔有率（按疾病適應症分類）(%)
  • 愛滋病
  • 肝炎
  • 鉅細胞病毒（CMV）

第9章：全球抗病毒藥物抗藥性市場分析及技術分析

  • 概述
  • 2018 年及 2031 年全球抗病毒藥物抗藥性市場佔有率（按技術分類）
  • 免疫診斷
  • 聚合酶鍊式反應（PCR）
  • 下一代定序（NGS）
  • 其他技術

第10章：全球抗病毒藥物抗藥性市場分析及最終用戶分類

  • 概述
  • 2018 年及 2031 年全球抗病毒藥物抗藥性市場佔有率（按最終用戶分類）(%)
  • 醫院和診所
  • 病理學和診斷實驗室
  • 研究機構

第11章：抗病毒藥物抗藥性市場收入及至2031年預測與地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
  • 南美洲和中美洲
    • 南美洲和中美洲
    • 阿根廷
    • 巴西

第12章：抗病毒藥物抗藥性市場及產業概況

  • 概述

第13章：抗病毒藥物抗藥性市場及主要公司概況

  • AccuBioTech Co., Ltd.
  • ACON Laboratories, Inc.
  • Siemens AG
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • Abbott
  • BD
  • F. Hoffmann-La Roche Ltd.
  • Trinity Biotech

第14章：附錄

簡介目錄
Product Code: TIPRE00006395

The market for antiviral drug resistance is anticipated to grow from US$ 3.71 billion in 2024 to US$ 6.35 billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.9% during the period from 2031 to 2031. Key trends driving this market include the rising incidence of liver diseases, the ongoing prevalence of HIV and AIDS, and the increasing demand for high-quality products in developing countries.

Analysis of the Antiviral Drug Resistance Market

Globally, the prevalence of HIV/AIDS has seen a significant rise in recent years. Acquired immunodeficiency syndrome (AIDS), a chronic and potentially fatal condition, is caused by the human immunodeficiency virus (HIV), which severely compromises the immune system and hinders the body's ability to combat infections. Following the entry of HIV into the body, individuals may experience flu-like symptoms within a month, known as primary or acute HIV infection, which can last for several weeks. According to the US Department of Health & Human Services and the Secretary's Minority AIDS Initiative Fund (SMAIF), approximately 39 million individuals were living with HIV/AIDS globally in 2022, with a significant proportion residing in low- and middle-income countries. For example, the India HIV Estimation 2017 report (National Informatics Centre) estimates the HIV prevalence in India at 0.22% (ranging from 0.16% to 0.30%). Furthermore, the adult HIV prevalence is estimated at 0.25% (0.18%-0.34%) among males and 0.19% (0.14%-0.25%) among females. Consequently, the rising cases of viral infections in India are expected to boost the demand for antiviral drug resistance solutions during the forecast period.

Overview of the Antiviral Drug Resistance Market

The increasing rates of hepatitis and the growing prevalence of HIV/AIDS are propelling market growth. Additionally, the expansion of emerging markets is likely to positively influence demand during the forecast period. However, market growth may be hindered by alternative treatment approaches. In the United States, the prevalence of HIV has risen in recent years. Data from the US Department of Health & Human Services and the SMAIF indicates that nearly 32,100 Americans were newly diagnosed with HIV in 2021. These factors are expected to drive the growth of the antiviral drug resistance market in North America throughout the forecast period.

Strategic Insights

Drivers and Opportunities in the Antiviral Drug Resistance Market

Increasing Incidence of Hepatic Diseases to Benefit the Market

Viruses, which are microscopic pathogens, can lead to various infectious diseases, including the flu, common cold, and warts, as well as severe conditions like smallpox, HIV/AIDS, and Ebola. They replicate within host cells and can invade any healthy living cells, multiplying and producing more viruses. Different viruses target specific cells in the body, such as those in the liver, brain, skin, blood, and various systems including reproductive, respiratory, and gastrointestinal. The incidence of viral infections, particularly hepatitis, has risen globally in recent years. Hepatitis can cause liver damage and inflammation, posing a significant global health challenge that can lead to chronic infections and increased mortality risk from cirrhosis and liver cancer. Hepatitis is classified into types A, B, C, D, and E, each with different transmission methods. According to the World Health Organization (WHO), the highest prevalence of Hepatitis B is found in the African and Western Pacific regions, with infection rates of 6.1% and 6.2% among the adult populations, respectively.

Rising Healthcare Investments in Emerging Markets

Growing healthcare expenditures in emerging markets, particularly in the Asia Pacific and South and Central America, are facilitating the development of treatment options for various viral diseases through advanced techniques such as PCR (Polymerase Chain Reaction) and next-generation sequencing. Organizations like the National Cancer Institute (NCI) are funding research on HIV and AIDS-related malignancies to understand how aging with chronic HIV infections affects cancer risk, spectrum, and biology. Countries like China, Japan, and Brazil are significantly investing in healthcare to enhance their market presence and ensure the effective use of medical instruments and reagents in hospitals, research institutes, and diagnostic laboratories.

Segmentation Analysis of the Antiviral Drug Resistance Market

The antiviral drug resistance market analysis is segmented by type, disease indication, technology, and end users.

  • By type, the market is categorized into kits and reagents, and instruments, with kits and reagents holding the largest market share in 2023.
  • By disease indication, the market is divided into HIV, hepatitis, and Cytomegalovirus (CMV), with the HIV segment commanding the largest share in 2023.
  • In terms of technology, the market includes immunodiagnostics, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others, with immunodiagnostics holding a significant market share in 2023.
  • By end users, the market is segmented into hospitals and clinics, pathology or diagnostic laboratories, and research institutes, with hospitals and clinics representing the largest share in 2023.

Geographical Analysis of the Antiviral Drug Resistance Market

The geographical scope of the antiviral drug resistance market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. North America holds the largest market share for antiviral drug resistance, driven by factors such as the prevalence of viral infections like HIV and hepatitis, as well as government-funded national programs. The incidence of HIV in the US has risen in recent years, with approximately 32,100 new infections reported in 2021. The Asia Pacific region is expected to experience the highest CAGR in the coming years.

Scope of the Antiviral Drug Resistance Market Report

Recent Developments in the Antiviral Drug Resistance Market

The antiviral drug resistance market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Notable developments in the antiviral drug resistance market include:

  • Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of new data in the journal Nature, indicating that an early-stage clinical candidate (JNJ-1802) offers strong protection against dengue in non-human primates and mice. This first-in-class antiviral, which was found to be safe and well-tolerated in a Phase 1 clinical study, is advancing to Phase 2 clinical trials for dengue prevention and treatment. (Source: Johnson & Johnson, Press Release, March 2023)
  • Cipla Limited received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for the launch of Molnupiravir in India, which will be marketed under the brand name Cipmolnu(R). Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for treating mild-to-moderate COVID-19 in patients at high risk of severe disease. (Source: Cipla, Press Release, May 2021)

Coverage and Deliverables of the Antiviral Drug Resistance Market Report

The report titled "Antiviral Drug Resistance Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

  • Market size and forecast for antiviral drug resistance at global, regional, and country levels across all key segments.
  • Market trends and dynamics, including drivers, restraints, and key opportunities.
  • Detailed PEST/Porter's Five Forces and SWOT analysis.
  • Market analysis covering key trends, global and regional frameworks, major players, regulations, and recent developments.
  • Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments in the antiviral drug resistance market.
  • In-depth company profiles.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Antiviral Drug Resistance Market and By Product
    • 1.3.2 Global Antiviral Drug Resistance Market and By Disease Indication
    • 1.3.3 Global Antiviral Drug Resistance Market and By Technology
    • 1.3.4 Global Antiviral Drug Resistance Market and By End User
    • 1.3.5 Global Antiviral Drug Resistance Market and By Geography

2. Global Antiviral Drug Resistance Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Global Antiviral Drug Resistance Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America PEST Analysis
    • 4.2.2 Europe PEST Analysis
    • 4.2.3 Asia Pacific PEST Analysis
    • 4.2.4 Middle East and Africa PEST Analysis
    • 4.2.5 South and Central America PEST Analysis
  • 4.3 Expert Opinion
  • 4.4 Cost of Test, By Test Type
  • 4.5 Test Volume, By Region

5. Global Antiviral Drug Resistance Market and Key Industry Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Rise in the Incidences of Hepatitis Diseases
    • 5.1.2 Increasing Prevalence of HIV/AIDS
  • 5.2 Key Market Restraints
    • 5.2.1 Alternative Approaches
  • 5.3 Key Market Opportunities
    • 5.3.1 Increasing Healthcare Expenditures in Emerging Markets
  • 5.4 Future Trends
    • 5.4.1 Demand For Higher Quality Products
  • 5.5 Impact Analysis

6. Antiviral Drug Resistance Market and Global Analysis

  • 6.1 Global Antiviral Drug Resistance Market Revenue Forecasts And Analysis
  • 6.2 Global Antiviral Drug Resistance Market, By Geography - Forecasts And Analysis
  • 6.3 Positioning of Key Players

7. Global Antiviral Drug Resistance Market Analysisand by Product

  • 7.1 Overview
  • 7.2 Global Antiviral Drug Resistance Market Share by Product 2018 and 2031 (%)
  • 7.3 Kits and Reagents
    • 7.3.1 Overview
    • 7.3.2 Kits and Reagents Market Revenue and Forecast to 2031 (US$ Mn)
  • 7.4 Instruments
    • 7.4.1 Overview
    • 7.4.2 Instruments Market Revenue and Forecast to 2031 (US$ Mn)

8. Global Antiviral Drug Resistance Market Analysisand by Disease Indication

  • 8.1 Overview
  • 8.2 Global Antiviral Drug Resistance Market Share by Disease Indication 2018 and 2031 (%)
  • 8.3 HIV
    • 8.3.1 Overview
    • 8.3.2 HIV Market Revenue and Forecast to 2031 (US$ Mn)
  • 8.4 Hepatitis
    • 8.4.1 Overview
    • 8.4.2 Hepatitis Market Revenue and Forecast to 2031 (US$ Mn)
  • 8.5 Cytomegalovirus (CMV)
    • 8.5.1 Overview
    • 8.5.2 Cytomegalovirus (CMV) Market Revenue and Forecast to 2031 (US$ Mn)

9. Global Antiviral Drug Resistance Market Analysisand by Technology

  • 9.1 Overview
  • 9.2 Global Antiviral Drug Resistance Market Share by Technology 2018 and 2031 (%)
  • 9.3 Immunodiagnostics
    • 9.3.1 Overview
    • 9.3.2 Immunodiagnostics Market Revenue and Forecast to 2031 (US$ Mn)
  • 9.4 Polymerase Chain Reaction (PCR)
    • 9.4.1 Overview
    • 9.4.2 Polymerase Chain Reaction (PCR) Market Revenue and Forecast to 2031 (US$ Mn)
  • 9.5 Next Generation Sequencing (NGS)
    • 9.5.1 Overview
    • 9.5.2 Next Generation Sequencing (NGS) Market Revenue and Forecast to 2031 (US$ Mn)
  • 9.6 Other Technologies
    • 9.6.1 Overview
    • 9.6.2 Other Technologies Market Revenue and Forecast to 2031 (US$ Mn)

10. Global Antiviral Drug Resistance Market Analysisand by End User

  • 10.1 Overview
  • 10.2 Global Antiviral Drug Resistance Market Share by End User 2018 and 2031 (%)
  • 10.3 Hospitals and Clinics
    • 10.3.1 Overview
    • 10.3.2 Hospitals And Clinics Market Revenue and Forecast to 2031 (US$ Mn)
  • 10.4 Pathology and Diagnostic Laboratories
    • 10.4.1 Overview
    • 10.4.2 Pathology and Diagnostic Laboratories Market Revenue and Forecast to 2031 (US$ Mn)
    • 10.4.3 List of Laboratories, By Region
  • 10.5 Research Institutes
    • 10.5.1 Overview
    • 10.5.2 Research Institutes Market Revenue and Forecast to 2031 (US$ Mn)

11. Antiviral Drug Resistance Market Revenue and Forecasts to 2031 and Geographical Analysis

  • 11.1 North America Antiviral Drug Resistance Market Revenue And Forecasts To 2031
    • 11.1.1 North America Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
    • 11.1.2 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
    • 11.1.3 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
    • 11.1.4 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
    • 11.1.5 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.1.6 North America Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
    • 11.1.7 US Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.7.1 US Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.7.2 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.1.7.3 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.1.7.4 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.1.7.5 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.1.8 Canada Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.8.1 Canada Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.8.2 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.1.8.3 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.1.8.4 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.1.8.5 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.1.9 Mexico Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.9.1 Mexico Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.9.2 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.1.9.3 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.1.9.4 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.1.9.5 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
  • 11.2 Europe Antiviral Drug Resistance Market Revenue And Forecasts To 2031
    • 11.2.1 Europe Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
    • 11.2.2 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
    • 11.2.3 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
    • 11.2.4 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
    • 11.2.5 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.2.6 Europe Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
    • 11.2.7 UK Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.7.1 UK Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.7.2 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.2.7.3 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.2.7.4 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.2.7.5 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.2.8 Germany Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.8.1 Germany Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.8.2 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.2.8.3 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.2.8.4 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.2.8.5 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.2.9 France Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.9.1 France Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.9.2 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.2.9.3 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.2.9.4 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.2.9.5 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.2.10 Italy Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.10.1 Italy Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.10.2 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.2.10.3 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.2.10.4 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.2.10.5 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.2.11 Spain Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.11.1 Spain Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.11.2 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.2.11.3 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.2.11.4 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.2.11.5 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
  • 11.3 Asia Pacific Antiviral Drug Resistance Market Revenue and Forecasts to 2031
    • 11.3.1 Asia Pacific Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
    • 11.3.2 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
    • 11.3.3 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
    • 11.3.4 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
    • 11.3.5 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.3.6 Asia Pacific Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
    • 11.3.7 Japan Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.7.1 Japan Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.7.2 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.3.7.3 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.3.7.4 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.3.7.5 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.3.8 China Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.8.1 China Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.8.2 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.3.8.3 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.3.8.4 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.3.8.5 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.3.9 India Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.9.1 India Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.9.2 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.3.9.3 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.3.9.4 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.3.9.5 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.3.10 South Korea Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.10.1 South Korea Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.10.2 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.3.10.3 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.3.10.4 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.3.10.5 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.3.11 Australia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.11.1 Australia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.11.2 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.3.11.3 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.3.11.4 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.3.11.5 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
  • 11.4 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts To 2031
    • 11.4.1 Middle East and Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
    • 11.4.2 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
    • 11.4.3 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
    • 11.4.4 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
    • 11.4.5 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.4.6 Middle East and Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
    • 11.4.7 UAE Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.7.1 UAE Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.7.2 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.4.7.3 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.4.7.4 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.4.7.5 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.4.8 Saudi Arabia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.8.1 Saudi Arabia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.8.2 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.4.8.3 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.4.8.4 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.4.8.5 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.4.9 South Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.9.1 South Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.9.2 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.4.9.3 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.4.9.4 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.4.9.5 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
  • 11.5 South And Central America Antiviral Drug Resistance Market Revenue And Forecasts To 2031
    • 11.5.1 South and Central America Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
    • 11.5.2 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
    • 11.5.3 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
    • 11.5.4 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
    • 11.5.5 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.5.6 South and Central America Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
    • 11.5.7 Argentina Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.5.7.1 Argentina Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.5.7.2 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.5.7.3 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.5.7.4 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.5.7.5 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.5.8 Brazil Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.5.8.1 Brazil Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.5.8.2 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.5.8.3 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.5.8.4 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.5.8.5 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)

12. Antiviral Drug Resistance Marketand Industry Landscape

  • 12.1 Overview

13. Antiviral Drug Resistance MarketandKey Company Profiles

  • 13.1 AccuBioTech Co., Ltd.
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Financial Overview
    • 13.1.4 Product Portfolio
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 ACON Laboratories, Inc.
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Financial Overview
    • 13.2.4 Product Portfolio
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Siemens AG
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Financial Overview
    • 13.3.4 Product Portfolio
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 bioMerieux SA
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Financial Information
    • 13.4.4 Product Portfolio
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Bio-Rad Laboratories, Inc.
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Financial Information
    • 13.5.4 Product Portfolio
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Danaher
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Financial Overview
    • 13.6.4 Product Portfolio
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Abbott
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Financial Overview
    • 13.7.4 Product Portfolio
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 BD
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Financial Overview
    • 13.8.4 Product Portfolio
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 F. Hoffmann-La Roche Ltd.
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Financial Overview
    • 13.9.4 Product Portfolio
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Trinity Biotech
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Financial Overview
    • 13.10.4 Product Portfolio
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms